Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Wednesday Is Your Last Chance To Buy Global Medical REIT Before The Dividend Payout
Wednesday marks the last chance for investors to receive the next dividend payout from Global Medical REIT (NYSE:GMRE).
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Global Medical REIT Q3 Adj. FFO $0.24 Up From $0.23 YoY, Sales $29.98M Beat $29.29M Estimate
Global Medical REIT (NYSE:GMRE) reported quarterly earnings of $0.24 per share. This is a 4.35 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Keybanc Initiates Coverage On Global Medical REIT with Overweight Rating, Announces Price Target of $17
Keybanc analyst Jordan Sadler initiates coverage on Global Medical REIT (NYSE:GMRE) with a Overweight rating and announces Price Target of $17.
Global Medical REIT Q2 FFO $0.22 Up From $0.19 YoY, Sales $28.20M Miss $28.63M Estimate
Global Medical REIT (NYSE:GMRE) reported quarterly earnings of $0.22 per share. This is a 15.79 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Colliers Securities Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $18
Colliers Securities analyst Barry Oxford initiates coverage on Global Medical REIT (NYSE:GMRE) with a Buy rating and announces Price Target of $18.